Jumbo pumpkin seeds from Canada could be contaminated with salmonella
Advantage Health Matters, with headquarters in Ontario, Canada, is recalling its 8-ounce packages of Organic Traditions Jumbo Pumpkin Seeds.
The seeds "have the potential to be contaminated with salmonella," the FDA said in its recall announcement.
Salmonella is one of the leading causes of foodborne illnesses worldwide, according to the U.S. Centers for Disease Control and Prevention (CDC).
Symptoms of salmonella include fever, diarrhea, nausea, vomiting and stomach cramps, the CDC said.
It can also cause "serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems," according to the FDA.
The recalled pumpkin seeds were distributed in the states of New York, New Jersey and Virginia in retail stores and through mail orders.
They come in an 8-ounce, clear plastic package with the lot number L250320200 on the back and an expiration date of May 2, 2027, stamped on the side.
"This recall was triggered by a recall of a supplier in another country," according to the FDA.
Although no illnesses have been reported, production "has been suspended" while the company investigates the source of the problem, the FDA stated.
Anyone who has purchased the recalled pumpkin seeds is "urged to return them to the place of purchase for a full refund."
Fox News Digital reached out to Advantage Health Matters for comment on the recall.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Implantica publishes Interim Report January - June 2025 (Q2)
VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA PMA Submission Completed - Submitted third and final module of the U.S. FDA pre-market approval (PMA) application for RefluxStop®, including responses to questions on the second module; Feedback on module 3 expected in the near-term Produced and completed initial testing on new multi-cavity production tool for RefluxStop® to support launch of manufacturing in U.S. and manage ramp-up of U.S. production (pending FDA approval) Additional preparations for U.S. market launch (pending FDA approval) included U.S. payer and reimbursement activities, finalizing new production facility of RefluxStop® in U.S. and launching our RCT (randomized clinical trial), as a heavyweight cornerstone in building global leadership in acid reflux care Positive NICE Guidance in the UK - UK's National Institute for Health and Care Excellence (NICE) issued positive guidance for the use of RefluxStop® in NHS hospitals for patients with ineffective esophageal motility (IOM/IEM), potentially transforming treatment access for millions and influencing global policy Significant events after the end of the period Landmark 5-Year Clinical Study Results - Two peer-reviewed articles were published in Surgical Endoscopy on our pivotal study results; one publication confirmed outstanding long-term safety and effectiveness outcomes, and the second publication highlighted RefluxStop®'s excellent outcomes in food passageway-related sequelae, which is common in standard of care Randomized Clinical Trial (RCT) Launch - First RCT comparing RefluxStop® with Nissen fundoplication; patient recruitment underway accumulating patients across participating hospitals. While this trial preparation led to a 20% year-on-year revenue decline for Q2, the impact is expected to ease once study recruitment stabilizes Spanish Market Expansion - Three new hospitals added, totaling 19 centers offering RefluxStop® in Spain, with a healthcare sytem receptive for new and better patient care, which is a fantastic launch since 2023 First UK National Users Meeting - Convened 21 top anti-reflux experts to discuss real-world results, operating technique and the opportunities arising from NICE's positive recommendation Financial summary second quarter 2025 Net sales decreased 22% to TEUR 433 (554) due to the launch of the randomized clinical trial with surgeons accumulating patients for the trial. Adjusted gross margin amounted to 90% (91%). Operating loss (EBIT) decreased to TEUR 4,525 (5,869). Loss after tax decreased to TEUR 5,448 (6,431). Basic and diluted loss per Class A share amounted to EUR 0.08 (0.09). Cash and short-term investments as at the end of the period of MEUR 56.3. First six months Net sales increased 2% to TEUR 1,178 (1,150). Adjusted gross margin amounted to 94% (91%). Operating loss (EBIT) decreased to TEUR 8,698 (12,956). Loss after tax decreased to TEUR 8,212 (9,903). Basic and diluted loss per Class A share amounted to EUR 0.12 (0.14). Telephone conference Implantica will hold a teleconference on 14 August 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to participate via webcast, please use the following link: Dial-in Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference. For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-14 08:00 CEST. About Implantica: Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop®, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. This information was brought to you by Cision The following files are available for download: Implantica Q2 2025_ENG Implantica publishes Interim Report Jan - Jun 2025 Q2 View original content:
Yahoo
an hour ago
- Yahoo
CDC director: Misinformation 'lead to deadly consequence" in Atlanta
Aug. 13 (UPI) -- The director of the Centers for Disease Control and Prevention told employees about the dangers of misinformation, four days after a suspected gunman shot at the agency's headquarters in Atlanta, claiming the COVID-19 vaccine made him sick. On Tuesday, Susan Monarez met with staffers virtually and then sent a note to all 10,000 employees nationwide, obtained by ABC News. Staffers at the headquarters have been working remotely since the attack on Friday. "The dangers of misinformation and its promulgation has now led to deadly consequences," she wrote. "I will work to restore trust in public health to those who have lost it -- through science, evidence and clarity of purpose. I will need your help." The comments were slightly different than those during her staff meeting in which she said: "Public health should never be under attack. We know that misinformation can be dangerous." She said the health agency can rebuild trust with "rational evidence-based discourse" with "compassion and understanding." Dr. Paul Offit, the director of the Vaccine Education Center at Children's Hospital of Pennsylvania, told NBC News: "The irony is her boss is the biggest spreader of misinformation." Robert F. Kennedy Jr. is secretary of the Health and Human Services, which oversees the CDC. In 2021, during the pandemic, Kennedy described the shot as the "deadliest vaccine ever made" after he filed a citizens' petition requesting that the Food and Drug Administration end emergency authorization. Last week, Kennedy announced that HHS was moving to terminate $500 million in contracts to develop vaccines using mRNA technology, which was used to develop the COVID-19 vaccine in 2020. "After reviewing the science and consulting top experts at NIH [National Institutes of Health] and FDA, HHS has determined that mRNA technology poses more risks than benefits for these respiratory viruses," The American Medical Association backs mRNA vaccine research and the CDC still says on its website: "During the COVID-19 pandemic, COVID-19 vaccines underwent the most intensive safety analysis in U.S. history." Health officials have denounced skepticism of the research, noting the COVID-19 vaccine saved millions of lives in the United States. "The Covid pandemic showed us what's possible when science moves fast," Rick Bright, who directed the Biomedical Advanced Research and Development from 2016 to 2020, told NBC News. "Dismantling that momentum now is like disbanding the fire department because the fire's out." As head of the HHS, he has updated COVID-19 vaccine recommendations for the fall to be restricted to older adults and those with underlying health conditions. He also doesn't want children to get the shots. On Monday, Kennedy toured the CDC campus in Atlanta and met with the widow of the one person slain in the attack, DeKalb County Police Officer David Rose. He toured with Monarez and HHS Deputy Secretary Jim O'Neill. "He offered his deepest condolences and reaffirmed the agency's commitment to honoring officer Rose's bravery, sacrifice and service to the nation," HHS said. Since the attack, the union representing CDC workers condemned the lack of support from top officials. "This leadership is critical in reinforcing public trust and ensuring that accurate, science-based information prevails," the union said Sunday. "This condemnation is necessary to help prevent violence against scientists that may be incited by such disinformation." The American Federation of Government Employees Local 2883, which represents more than 2,000 CDC workers, said in a statement Sunday that the attack "was not random and it compounds months of mistreatment, neglect and vilification that CDC staff have endured." The union also said: "The deliberate targeting of CDC through this violent act is deeply disturbing, completely unacceptable and an attack on every public servant." The father of the suspected gunman, 30-year-old Patrick Joseph White, reportedly told authorities he targeted the CDC over health problems he blamed on the COVID-19 vaccine. He said the shot made him depressed and suicidal. He was fatally shot by police after around 200 bullets struck the six buildings. Five firearms were recovered. "All indications are that this was an isolated event involving one individual," Jeff Williams, the deputy secretary of the CDC's Office of Safety, Security and Asset Management, said during the staff meeting Tuesday.
UPI
an hour ago
- UPI
CDC director: Misinformation 'lead to deadly consequence" in Atlanta
The U.S. Centers for Disease Control and Prevention headquarters in Atlanta was attacked by a gunman on Friday. File Photo by Erike S. Lesser/EPA Aug. 13 (UPI) -- The director of the Centers for Disease Control and Prevention told employees about the dangers of misinformation, four days after a suspected gunman shot at the agency's headquarters in Atlanta, claiming the COVID-19 vaccine made him sick. On Tuesday, Susan Monarez met with staffers virtually and then sent a note to all 10,000 employees nationwide, obtained by ABC News. Staffers at the headquarters have been working remotely since the attack on Friday. "The dangers of misinformation and its promulgation has now led to deadly consequences," she wrote. "I will work to restore trust in public health to those who have lost it -- through science, evidence and clarity of purpose. I will need your help." The comments were slightly different than those during her staff meeting in which she said: "Public health should never be under attack. We know that misinformation can be dangerous." She said the health agency can rebuild trust with "rational evidence-based discourse" with "compassion and understanding." Dr. Paul Offit, the director of the Vaccine Education Center at Children's Hospital of Pennsylvania, told NBC News: "The irony is her boss is the biggest spreader of misinformation." Robert F. Kennedy Jr. is secretary of the Health and Human Services, which oversees the CDC. In 2021, during the pandemic, Kennedy described the shot as the "deadliest vaccine ever made" after he filed a citizens' petition requesting that the Food and Drug Administration end emergency authorization. Last week, Kennedy announced that HHS was moving to terminate $500 million in contracts to develop vaccines using mRNA technology, which was used to develop the COVID-19 vaccine in 2020. "After reviewing the science and consulting top experts at NIH [National Institutes of Health] and FDA, HHS has determined that mRNA technology poses more risks than benefits for these respiratory viruses," The American Medical Association backs mRNA vaccine research and the CDC still says on its website: "During the COVID-19 pandemic, COVID-19 vaccines underwent the most intensive safety analysis in U.S. history." Health officials have denounced skepticism of the research, noting the COVID-19 vaccine saved millions of lives in the United States. "The Covid pandemic showed us what's possible when science moves fast," Rick Bright, who directed the Biomedical Advanced Research and Development from 2016 to 2020, told NBC News. "Dismantling that momentum now is like disbanding the fire department because the fire's out." As head of the HHS, he has updated COVID-19 vaccine recommendations for the fall to be restricted to older adults and those with underlying health conditions. He also doesn't want children to get the shots. On Monday, Kennedy toured the CDC campus in Atlanta and met with the widow of the one person slain in the attack, DeKalb County Police Officer David Rose. He toured with Monarez and HHS Deputy Secretary Jim O'Neill. "He offered his deepest condolences and reaffirmed the agency's commitment to honoring officer Rose's bravery, sacrifice and service to the nation," HHS said. Today I traveled to Atlanta in the wake of the heartbreaking shooting at the CDC's Roybal Campus that took the life of DeKalb County Police Officer David Rose. @POTUS and the entire administration are deeply saddened by this tragic loss. We stand with Officer Rose's wife, his two... Secretary Kennedy (@SecKennedy) August 11, 2025 Since the attack, the union representing CDC workers condemned the lack of support from top officials. "This leadership is critical in reinforcing public trust and ensuring that accurate, science-based information prevails," the union said Sunday. "This condemnation is necessary to help prevent violence against scientists that may be incited by such disinformation." The American Federation of Government Employees Local 2883, which represents more than 2,000 CDC workers, said in a statement Sunday that the attack "was not random and it compounds months of mistreatment, neglect and vilification that CDC staff have endured." The union also said: "The deliberate targeting of CDC through this violent act is deeply disturbing, completely unacceptable and an attack on every public servant." The father of the suspected gunman, 30-year-old Patrick Joseph White, reportedly told authorities he targeted the CDC over health problems he blamed on the COVID-19 vaccine. He said the shot made him depressed and suicidal. He was fatally shot by police after around 200 bullets struck the six buildings. Five firearms were recovered. "All indications are that this was an isolated event involving one individual," Jeff Williams, the deputy secretary of the CDC's Office of Safety, Security and Asset Management, said during the staff meeting Tuesday.
